Current FDA labeling for semaglutide products includes warnings or precautions involving: Acute pancreatitis Acute gallbladder disease Acute kidney injury due to volume depletion Severe gastrointestinal reactions Hypoglycemia when combined with insulin or insulin secretagogues Diabetic retinopathy complications in susceptible patients Serious hypersensitivity reactions Pulmonary aspiration risk during general anesthesia or deep sedation Semaglutide labeling also contains a boxed warning regarding thyroid C-cell tumors observed in rodents
Patients should maintain a record of injection sites and any reactions, which can help healthcare professionals identify patterns and optimise injection technique
Youll just need to fill out a short consultation, so our clinicians can assess whether injections are the right fit for you
This bears repeating because it is that important
FDA-Approved GLP-1 Medications for Weight Loss FDA-approved GLP-1 receptor agonists used for chronic weight management include Wegovy, which contains semaglutide, and Saxenda, which contains liraglutide
The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second included 8942 patients who started SGLT-2 inhibitors and added on GLP-1 receptor agonists
